Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ahnfelt

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Thrombosis and Haemostasis : JTH|August 31, 2004
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IB I Eriksson, O E Dahl, L Ahnfelt, et al.
Lakartidningen|September 21, 1988
[Symposium. New hip joints: an explosion-like development]B Nilsson, L Ahnfelt, T Albrektsson, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2005
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialB I Eriksson, O E Dahl, H R Büller, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Thrombosis and Haemostasis : JTH|August 31, 2004
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IB I Eriksson, O E Dahl, L Ahnfelt, et al.
Lakartidningen|September 21, 1988
[Symposium. New hip joints: an explosion-like development]B Nilsson, L Ahnfelt, T Albrektsson, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2005
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialB I Eriksson, O E Dahl, H R Büller, et al.
Pageof 2